Selective Class IIa HDAC Inhibitors for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by histone deacetylases (HDACs) lack effective inhibitors that can selectively target specific HDAC classes, such as Class IIa HDACs, which are implicated in various diseases including neurodegenerative disorders, fibrosis, and cancer, without causing unintended biological effects.
Innovation Solution
Development of specific HDAC inhibitors, represented by compounds of Formula I and their pharmaceutically acceptable salts, which selectively inhibit Class IIa HDACs, including HDAC4, HDAC5, and HDAC9, by interacting with these enzymes to reduce their catalytic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HDAC inhibitors are used, then broad HDAC inhibition is achieved, but selective targeting of Class IIa HDACs is lost and unintended biological effects occur
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that selectively interact with Class IIa HDACs. The compounds contain particular structural elements (such as hydroxamic acid groups combined with specific aromatic moieties) that create localized binding affinity for Class IIa HDAC active sites while avoiding other HDAC classes, thereby achieving selective inhibition without broad-spectrum effects
Solution Approach 2:
The patent employs parameter changes by modifying key molecular parameters of HDAC inhibitors, including substituent types, positions, and electronic properties. By systematically varying these parameters in the chemical structures, the patent optimizes selectivity for Class IIa HDACs while maintaining inhibitory potency, thus resolving the contradiction between broad inhibition and selective targeting
2Reliability
If selective Class IIa HDAC inhibitors are developed, then specific disease targets are achieved, but treatment efficacy for conditions requiring broad HDAC inhibition may be reduced
Solution Approach 1:
The patent applies segmentation by dividing the HDAC enzyme family into distinct target groups (Class I, IIa, IIb, IV) and developing specialized inhibitors for each class. The selective Class IIa inhibitors presented in the patent target specific diseases where Class IIa HDACs are implicated, while acknowledging that different HDAC classes may be targeted by different compounds in comprehensive treatment regimens, thus maintaining overall therapeutic effectiveness through class-specific approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit Class IIa HDACs, providing therapeutic benefits for conditions like neurodegenerative diseases, fibrosis, and cancer by selectively targeting these enzymes, thereby ameliorating symptoms and slowing disease progression without broad, non-specific biological effects.
Implementation Method 1
specific HDAC inhibitors, represented by compounds of Formula I and their pharmaceutically acceptable salts, which selectively inhibit Class IIa HDACs, including HDAC4, HDAC5, and HDAC9, by interacting with these enzymes to reduce their catalytic activity
Data Source
AI summary
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.